Wada Yuko, Ohno Seiko, Aiba Takeshi, Horie Minoru
Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan.
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Mol Genet Genomic Med. 2017 Nov;5(6):639-651. doi: 10.1002/mgg3.311. Epub 2017 Aug 13.
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy mainly caused by desmosomal gene mutation. More than half of Caucasian probands have desmosomal mutations, which lead to earlier onset of ventricular arrhythmias. Among non-Caucasians, the genetic background of ARVD/C probands and its prognostic impact remain unclear.
We genotyped 99 unrelated Japanese ARVD/C probands for plakophilin 2 (PKP2), desmoglein 2 (DSG2), desmoplakin (DSP), and desmocollin 2 (DSC2) between 2005 and 2014. Seventy-five probands who fulfilled "definite" category according to the 2010 Task Force Criteria (TFC) were enrolled and followed up for 6.4 years. Sixty-four percent of probands had desmosomal mutations; DSG2 was predominant (48% of mutations) followed by PKP2 (38%). DSG2 mutations were almost missense, whereas over 90% of PKP2 mutations were truncating mutations. Lethal ventricular arrhythmias (VAs, sustained ventricular tachycardia/fibrillation) occurred in 57% of probands as the first manifestation and 71% at the end of follow-up. Five died during follow-up. Truncating mutation carriers exhibited earlier lethal VAs onset compared to missense mutation carriers or mutation negatives (age at onset 35 ± 12, 49 ± 16, and 50 ± 19 years, respectively, P < 0.05 in each). Cox proportional hazard analysis revealed for the first time that, compared to mutation negatives, truncating mutation carriers had higher risk for lethal VAs, and especially for onset by their 40s, in an age-dependent manner (RR = 4.6, P < 0.01 by their 40s; RR = 2.9, P = 0.01 by their 50s).
The genetic background of Japanese ARVD/C probands is distinct from that of Caucasian probands, leading to distinct prognosis. The most affected gene mutations in Japanese probands were missense mutations in DSG2 leading to modest outcome, whereas PKP2 truncating mutations were the second most and might be a strong marker for lethal VAs in non-Caucasian Japanese ARVD/C probands.
致心律失常性右室心肌病(ARVD/C)是一种主要由桥粒基因突变引起的遗传性心肌病。超过一半的白种人先证者存在桥粒基因突变,这会导致室性心律失常更早发作。在非白种人中,ARVD/C先证者的遗传背景及其预后影响仍不清楚。
我们在2005年至2014年期间对99名无亲缘关系的日本ARVD/C先证者进行了盘状球蛋白2(PKP2)、桥粒芯糖蛋白2(DSG2)、桥粒斑蛋白(DSP)和桥粒芯胶蛋白2(DSC2)的基因分型。75名根据2010年工作组标准(TFC)符合“确诊”类别的先证者被纳入研究并随访6.4年。64%的先证者存在桥粒基因突变;DSG2最为常见(占突变的48%),其次是PKP2(占38%)。DSG2突变几乎均为错义突变,而超过90%的PKP2突变是截短突变。57%的先证者首次出现致命性室性心律失常(VAs,持续性室性心动过速/心室颤动),随访结束时这一比例为71%。随访期间有5人死亡。与错义突变携带者或无突变者相比,截短突变携带者出现致命性VAs的时间更早(发病年龄分别为35±12岁、49±16岁和50±19岁,各比较中P<0.05)。Cox比例风险分析首次显示,与无突变者相比,截短突变携带者发生致命性VAs的风险更高,尤其是在40多岁时,呈年龄依赖性(40多岁时风险比RR=4.6,P<0.01;50多岁时RR=2.9,P=0.01)。
日本ARVD/C先证者的遗传背景与白种人先证者不同,导致预后不同。日本先证者中受影响最严重的基因突变是DSG2的错义突变,导致预后一般,而PKP2截短突变次之,可能是日本非白种人ARVD/C先证者致命性VAs的有力标志物。